StartCell
INCREASING ACCESS TO HIGH QUALITY, COMMERCIALLY RELEVANT iPSC START MATERIAL
With their unlimited potential to expand and to create any cell type in the body, combined with the long-term freezer storage of cell therapy doses, iPSCs are the ultimate starting material for off-the-shelf cell therapy for many indications. Generation of commercially available iPSC-derived cell therapy for precision medicine is currently a costly, complex, and advance process. Not only are the processes of expanding and quality testing the iPSCs expensive, but they are also close to impossible to perform with current
technologies. StartCell will focus on addressing legal, commercial, and quality-control aspects of iPSC generation to lay the foundation for affordable cost to this start material in Sweden.
Coordinator: Lund University
Partners: Biolamina AB, CCRM Nordic, University of Skövde, IHE Institute for Health Economy, Karolinska Institutet, KTH, LU Innovation, Region Skåne, Karolinska Universitetssjukhuset, Takara Bio Europe AB, Novo Nordisk
WORKPACKAGES
- Legislation, IP, licensing, donor recruitment and screening
- Health economics and market access
- iPSC culturing and upscaling
- Novel quality controls and future release criteria
- Innovation and business scanning
- Management, communication and sustainability
Contact: Anna Falk, Lund University
Email: anna.falk@med.lu.se